Targeted therapy for skin lymphoma using a new immunotoxin
Official title: CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
Funded at Rock Immune, INC. · NIH-10850989 · Data updated 2026-11-12
This study is testing a new treatment for cutaneous T-cell lymphoma (CTCL) that uses a special therapy to help your immune system fight the cancer more effectively, and it could be a great option for patients whose CTCL hasn't responded to other treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rock Immune, INC. NIH-funded |
| Lab location | 1 site (Denver, United States) |
| Project start | August 1, 2021 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $248,336 |
| NIH project number | 5R42CA261547-04 |
| Project ID | NIH-10850989 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with refractory or recurrent cutaneous T-cell lymphoma who have not responded well to existing treatments.
✕Less likely to help
Patients with early-stage cutaneous T-cell lymphoma or those who have not been diagnosed with this specific type of cancer may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for cutaneous T-cell lymphoma (CTCL), a type of skin cancer characterized by malignant T lymphocytes causing skin lesions. The approach involves a bispecific immunotoxin that targets specific markers on cancer cells, aiming to enhance the immune response against the tumor. The therapy has shown promising results in preclinical models, significantly improving survival rates compared to existing treatments. Patients with refractory or recurrent CTCL may benefit from this innovative therapy.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with cutaneous T-cell lymphoma, potentially leading to better outcomes and improved quality of life.
How similar studies have gone: Other research has shown success with similar immunotoxin approaches in treating various cancers, indicating potential for this novel therapy.
Where this research is happening
-
Rock Immune, INC.
Denver, United States Active
Researchers
- Principal investigator: Wang, Zhirui — Rock Immune, INC.
- Study coordinator: Wang, Zhirui
Related research
Other NIH-funded projects on the same topics.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
-
Understanding how IL-15 affects T-cell lymphoma in the skin
This research explores how a specific signal, called IL-15, helps T-cell lymphoma cells move to and grow in the skin, aiming to find new ways to help patients with this condition.
-
New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma
This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.
-
Investigating how Staphylococcus aureus affects skin cancer development
This study is looking at how a common skin bacteria called Staphylococcus aureus might affect the growth of Cutaneous T-cell lymphomas (CTCL), a type of skin cancer, by examining the bacteria found on patients' skin to find new ways to understand and treat the disease.
-
Understanding how gene regulation affects cutaneous T cell lymphoma
This study is looking at how changes in DNA can affect a type of skin cancer called cutaneous T cell lymphoma, especially a severe form known as Sezary syndrome, to help find better ways to diagnose and treat it, and patients can help us learn more about how these changes might impact their treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.